Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
ObjectivesTo determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial.MethodsBetween November 2008 and June 2011, 133 patients were randomised to receive lithium carbonate (target blood l...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2012-05, Vol.83 (5), p.557-564 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 564 |
|---|---|
| container_issue | 5 |
| container_start_page | 557 |
| container_title | Journal of neurology, neurosurgery and psychiatry |
| container_volume | 83 |
| creator | Verstraete, Esther Veldink, Jan H Huisman, Mark H B Draak, Tim Uijtendaal, Esther V van der Kooi, Anneke J Schelhaas, H Jurgen de Visser, Marianne van der Tweel, Ingeborg van den Berg, Leonard H |
| description | ObjectivesTo determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial.MethodsBetween November 2008 and June 2011, 133 patients were randomised to receive lithium carbonate (target blood level 0.4–0.8 mEq/l) or placebo as add-on treatment with riluzole. The primary endpoint was survival, defined as death, tracheostomal ventilation or non-invasive ventilation for more than 16 h/day. Secondary outcome measures consisted of the revised ALS Functional Rating Scale and forced vital capacity. Analysis was by intention to treat and according to a sequential trial design.Results61 patients reached a primary endpoint, 33 of 66 in the lithium group and 28 of 67 patients in the placebo group. Lithium did not significantly affect survival (cumulative survival probability of 0.73 in the lithium group (95% CI 0.63 to 0.86) vs 0.75 in the placebo group (95% CI 0.65 to 0.87) at 12 months and 0.62 in the lithium group (95% CI 0.50 to 0.76) vs 0.67 in the placebo group (95% CI 0.56 to 0.81) at 16 months). Secondary outcome measures did not differ between treatment groups. No major safety concerns were encountered.ConclusionsThis trial, designed to detect a modest effect of lithium, did not demonstrate any beneficial effect on either survival or functional decline in patients with ALS.Trial registration numberNTR1448. Name of trial registry: Lithium trial in ALS. |
| doi_str_mv | 10.1136/jnnp-2011-302021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_993912338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1014099148</sourcerecordid><originalsourceid>FETCH-LOGICAL-b433t-cf5adaf3a6c6b2de61c8cd19fe52e5688308a48c64f16859739a4b213d85e0123</originalsourceid><addsrcrecordid>eNqF0cuL1TAUB-AginMd3buSgAsFqeYkfSSzk4uPixcVUXEX0vSUm05fJung_PemdJyFC80igeTLyeNHyGNgLwFE-aobxznjDCATjDMOd8gO8lJmQrAfd8mOMc7TSsHOyIMQOrY2qe6TM85FJRXIHemOLp7cMtDe2MtAsW3RRjqNNCz-yl2ZnrqRmuF6in6aT84mF9Gn6WB79FNw4YIaOp9MQHo41NSbsZkGF7ChAX8uOEaXcPSpf0jutaYP-OhmPCff3r75un-fHT-9O-xfH7M6FyJmti1MY1phSlvWvMESrLQNqBYLjkUppWDS5NKWeQulLFQllMlrDqKRBTLg4pw82-rOfko3CFGn-1jsezPitAStlFCJCZnk839KYJAzpSBf6dO_aDctfkzv0FBJ4LlkTCTFNmXT1wSPrZ69G4y_TqX0mpheE9NrYnpLLG15clN4qQdsbjf8iSiBbAMuRPx1u278pS4rURX64_e9ZvCh4IJ91l-Sf7H5euj-f_xv7nWuDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781248003</pqid></control><display><type>article</type><title>Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Verstraete, Esther ; Veldink, Jan H ; Huisman, Mark H B ; Draak, Tim ; Uijtendaal, Esther V ; van der Kooi, Anneke J ; Schelhaas, H Jurgen ; de Visser, Marianne ; van der Tweel, Ingeborg ; van den Berg, Leonard H</creator><creatorcontrib>Verstraete, Esther ; Veldink, Jan H ; Huisman, Mark H B ; Draak, Tim ; Uijtendaal, Esther V ; van der Kooi, Anneke J ; Schelhaas, H Jurgen ; de Visser, Marianne ; van der Tweel, Ingeborg ; van den Berg, Leonard H</creatorcontrib><description>ObjectivesTo determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial.MethodsBetween November 2008 and June 2011, 133 patients were randomised to receive lithium carbonate (target blood level 0.4–0.8 mEq/l) or placebo as add-on treatment with riluzole. The primary endpoint was survival, defined as death, tracheostomal ventilation or non-invasive ventilation for more than 16 h/day. Secondary outcome measures consisted of the revised ALS Functional Rating Scale and forced vital capacity. Analysis was by intention to treat and according to a sequential trial design.Results61 patients reached a primary endpoint, 33 of 66 in the lithium group and 28 of 67 patients in the placebo group. Lithium did not significantly affect survival (cumulative survival probability of 0.73 in the lithium group (95% CI 0.63 to 0.86) vs 0.75 in the placebo group (95% CI 0.65 to 0.87) at 12 months and 0.62 in the lithium group (95% CI 0.50 to 0.76) vs 0.67 in the placebo group (95% CI 0.56 to 0.81) at 16 months). Secondary outcome measures did not differ between treatment groups. No major safety concerns were encountered.ConclusionsThis trial, designed to detect a modest effect of lithium, did not demonstrate any beneficial effect on either survival or functional decline in patients with ALS.Trial registration numberNTR1448. Name of trial registry: Lithium trial in ALS.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp-2011-302021</identifier><identifier>PMID: 22378918</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd</publisher><subject>Activities of Daily Living ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Amyotrophic lateral sclerosis ; Amyotrophic Lateral Sclerosis - blood ; Amyotrophic Lateral Sclerosis - drug therapy ; Amyotrophic Lateral Sclerosis - mortality ; Blood levels ; carbonates ; Clinical trials ; Double-Blind Method ; Drug Therapy, Combination - adverse effects ; Female ; Humans ; Lithium ; Lithium Carbonate - adverse effects ; Lithium Carbonate - blood ; Lithium Carbonate - therapeutic use ; Male ; Middle Aged ; Motivation ; Neurosurgery ; Proteins ; Pulmonary Ventilation - drug effects ; Riluzole - therapeutic use ; Studies ; Survival ; Survival Rate ; Ventilation ; Vital Capacity - drug effects</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 2012-05, Vol.83 (5), p.557-564</ispartof><rights>2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b433t-cf5adaf3a6c6b2de61c8cd19fe52e5688308a48c64f16859739a4b213d85e0123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jnnp.bmj.com/content/83/5/557.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jnnp.bmj.com/content/83/5/557.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22378918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verstraete, Esther</creatorcontrib><creatorcontrib>Veldink, Jan H</creatorcontrib><creatorcontrib>Huisman, Mark H B</creatorcontrib><creatorcontrib>Draak, Tim</creatorcontrib><creatorcontrib>Uijtendaal, Esther V</creatorcontrib><creatorcontrib>van der Kooi, Anneke J</creatorcontrib><creatorcontrib>Schelhaas, H Jurgen</creatorcontrib><creatorcontrib>de Visser, Marianne</creatorcontrib><creatorcontrib>van der Tweel, Ingeborg</creatorcontrib><creatorcontrib>van den Berg, Leonard H</creatorcontrib><title>Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>ObjectivesTo determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial.MethodsBetween November 2008 and June 2011, 133 patients were randomised to receive lithium carbonate (target blood level 0.4–0.8 mEq/l) or placebo as add-on treatment with riluzole. The primary endpoint was survival, defined as death, tracheostomal ventilation or non-invasive ventilation for more than 16 h/day. Secondary outcome measures consisted of the revised ALS Functional Rating Scale and forced vital capacity. Analysis was by intention to treat and according to a sequential trial design.Results61 patients reached a primary endpoint, 33 of 66 in the lithium group and 28 of 67 patients in the placebo group. Lithium did not significantly affect survival (cumulative survival probability of 0.73 in the lithium group (95% CI 0.63 to 0.86) vs 0.75 in the placebo group (95% CI 0.65 to 0.87) at 12 months and 0.62 in the lithium group (95% CI 0.50 to 0.76) vs 0.67 in the placebo group (95% CI 0.56 to 0.81) at 16 months). Secondary outcome measures did not differ between treatment groups. No major safety concerns were encountered.ConclusionsThis trial, designed to detect a modest effect of lithium, did not demonstrate any beneficial effect on either survival or functional decline in patients with ALS.Trial registration numberNTR1448. Name of trial registry: Lithium trial in ALS.</description><subject>Activities of Daily Living</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Amyotrophic Lateral Sclerosis - blood</subject><subject>Amyotrophic Lateral Sclerosis - drug therapy</subject><subject>Amyotrophic Lateral Sclerosis - mortality</subject><subject>Blood levels</subject><subject>carbonates</subject><subject>Clinical trials</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Lithium</subject><subject>Lithium Carbonate - adverse effects</subject><subject>Lithium Carbonate - blood</subject><subject>Lithium Carbonate - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Motivation</subject><subject>Neurosurgery</subject><subject>Proteins</subject><subject>Pulmonary Ventilation - drug effects</subject><subject>Riluzole - therapeutic use</subject><subject>Studies</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Ventilation</subject><subject>Vital Capacity - drug effects</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0cuL1TAUB-AginMd3buSgAsFqeYkfSSzk4uPixcVUXEX0vSUm05fJung_PemdJyFC80igeTLyeNHyGNgLwFE-aobxznjDCATjDMOd8gO8lJmQrAfd8mOMc7TSsHOyIMQOrY2qe6TM85FJRXIHemOLp7cMtDe2MtAsW3RRjqNNCz-yl2ZnrqRmuF6in6aT84mF9Gn6WB79FNw4YIaOp9MQHo41NSbsZkGF7ChAX8uOEaXcPSpf0jutaYP-OhmPCff3r75un-fHT-9O-xfH7M6FyJmti1MY1phSlvWvMESrLQNqBYLjkUppWDS5NKWeQulLFQllMlrDqKRBTLg4pw82-rOfko3CFGn-1jsezPitAStlFCJCZnk839KYJAzpSBf6dO_aDctfkzv0FBJ4LlkTCTFNmXT1wSPrZ69G4y_TqX0mpheE9NrYnpLLG15clN4qQdsbjf8iSiBbAMuRPx1u278pS4rURX64_e9ZvCh4IJ91l-Sf7H5euj-f_xv7nWuDg</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Verstraete, Esther</creator><creator>Veldink, Jan H</creator><creator>Huisman, Mark H B</creator><creator>Draak, Tim</creator><creator>Uijtendaal, Esther V</creator><creator>van der Kooi, Anneke J</creator><creator>Schelhaas, H Jurgen</creator><creator>de Visser, Marianne</creator><creator>van der Tweel, Ingeborg</creator><creator>van den Berg, Leonard H</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial</title><author>Verstraete, Esther ; Veldink, Jan H ; Huisman, Mark H B ; Draak, Tim ; Uijtendaal, Esther V ; van der Kooi, Anneke J ; Schelhaas, H Jurgen ; de Visser, Marianne ; van der Tweel, Ingeborg ; van den Berg, Leonard H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b433t-cf5adaf3a6c6b2de61c8cd19fe52e5688308a48c64f16859739a4b213d85e0123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Activities of Daily Living</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Amyotrophic Lateral Sclerosis - blood</topic><topic>Amyotrophic Lateral Sclerosis - drug therapy</topic><topic>Amyotrophic Lateral Sclerosis - mortality</topic><topic>Blood levels</topic><topic>carbonates</topic><topic>Clinical trials</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Lithium</topic><topic>Lithium Carbonate - adverse effects</topic><topic>Lithium Carbonate - blood</topic><topic>Lithium Carbonate - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Motivation</topic><topic>Neurosurgery</topic><topic>Proteins</topic><topic>Pulmonary Ventilation - drug effects</topic><topic>Riluzole - therapeutic use</topic><topic>Studies</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Ventilation</topic><topic>Vital Capacity - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verstraete, Esther</creatorcontrib><creatorcontrib>Veldink, Jan H</creatorcontrib><creatorcontrib>Huisman, Mark H B</creatorcontrib><creatorcontrib>Draak, Tim</creatorcontrib><creatorcontrib>Uijtendaal, Esther V</creatorcontrib><creatorcontrib>van der Kooi, Anneke J</creatorcontrib><creatorcontrib>Schelhaas, H Jurgen</creatorcontrib><creatorcontrib>de Visser, Marianne</creatorcontrib><creatorcontrib>van der Tweel, Ingeborg</creatorcontrib><creatorcontrib>van den Berg, Leonard H</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verstraete, Esther</au><au>Veldink, Jan H</au><au>Huisman, Mark H B</au><au>Draak, Tim</au><au>Uijtendaal, Esther V</au><au>van der Kooi, Anneke J</au><au>Schelhaas, H Jurgen</au><au>de Visser, Marianne</au><au>van der Tweel, Ingeborg</au><au>van den Berg, Leonard H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>83</volume><issue>5</issue><spage>557</spage><epage>564</epage><pages>557-564</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>ObjectivesTo determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial.MethodsBetween November 2008 and June 2011, 133 patients were randomised to receive lithium carbonate (target blood level 0.4–0.8 mEq/l) or placebo as add-on treatment with riluzole. The primary endpoint was survival, defined as death, tracheostomal ventilation or non-invasive ventilation for more than 16 h/day. Secondary outcome measures consisted of the revised ALS Functional Rating Scale and forced vital capacity. Analysis was by intention to treat and according to a sequential trial design.Results61 patients reached a primary endpoint, 33 of 66 in the lithium group and 28 of 67 patients in the placebo group. Lithium did not significantly affect survival (cumulative survival probability of 0.73 in the lithium group (95% CI 0.63 to 0.86) vs 0.75 in the placebo group (95% CI 0.65 to 0.87) at 12 months and 0.62 in the lithium group (95% CI 0.50 to 0.76) vs 0.67 in the placebo group (95% CI 0.56 to 0.81) at 16 months). Secondary outcome measures did not differ between treatment groups. No major safety concerns were encountered.ConclusionsThis trial, designed to detect a modest effect of lithium, did not demonstrate any beneficial effect on either survival or functional decline in patients with ALS.Trial registration numberNTR1448. Name of trial registry: Lithium trial in ALS.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd</pub><pmid>22378918</pmid><doi>10.1136/jnnp-2011-302021</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3050 |
| ispartof | Journal of neurology, neurosurgery and psychiatry, 2012-05, Vol.83 (5), p.557-564 |
| issn | 0022-3050 1468-330X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_993912338 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Activities of Daily Living Adolescent Adult Aged Aged, 80 and over Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - blood Amyotrophic Lateral Sclerosis - drug therapy Amyotrophic Lateral Sclerosis - mortality Blood levels carbonates Clinical trials Double-Blind Method Drug Therapy, Combination - adverse effects Female Humans Lithium Lithium Carbonate - adverse effects Lithium Carbonate - blood Lithium Carbonate - therapeutic use Male Middle Aged Motivation Neurosurgery Proteins Pulmonary Ventilation - drug effects Riluzole - therapeutic use Studies Survival Survival Rate Ventilation Vital Capacity - drug effects |
| title | Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A59%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lithium%20lacks%20effect%20on%20survival%20in%20amyotrophic%20lateral%20sclerosis:%20a%20phase%20IIb%20randomised%20sequential%20trial&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Verstraete,%20Esther&rft.date=2012-05-01&rft.volume=83&rft.issue=5&rft.spage=557&rft.epage=564&rft.pages=557-564&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp-2011-302021&rft_dat=%3Cproquest_cross%3E1014099148%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781248003&rft_id=info:pmid/22378918&rfr_iscdi=true |